Cargando…

Comparing the efficacy of regen-cov, remdesivir, and favipiravir in reducing invasive mechanical ventilation need in hospitalized COVID-19 patients

BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021-year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, casirivimab and imdevi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hegazy, Sahar Kmal, Tharwat, Samar, Hassan, Ahmed Hosny
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Baishideng Publishing Group Inc 2023
Materias:	Clinical Trials Study
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10507553/ https://www.ncbi.nlm.nih.gov/pubmed/37731581 http://dx.doi.org/10.12998/wjcc.v11.i26.6105

Ejemplares similares

Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Retraction to “Study to compare the effect of casirivimab and imdevimab, remdesivir, and favipiravir on progression and multi-organ function of hospitalized COVID-19 patients”
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Clinical study to compare the efficacy and safety of casirivimab & imdevimab, remdesivir, and favipravir in hospitalized COVID-19 patients
por: Hegazy, Sahar K., et al.
Publicado: (2023)

Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir
por: Negru, Paul Andrei, et al.
Publicado: (2022)

Co-administration of Favipiravir and the Remdesivir Metabolite GS-441524 Effectively Reduces SARS-CoV-2 Replication in the Lungs of the Syrian Hamster Model
por: Chiba, Shiho, et al.
Publicado: (2022)

Effectiveness of Remdesivir, Lopinavir/Ritonavir, and Favipiravir for COVID-19 Treatment: A Systematic Review
por: Qomara, Windi Fresha, et al.
Publicado: (2021)

Effects of the RNA-Polymerase Inhibitors Remdesivir and Favipiravir on the Structure of Lipid Bilayers—An MD Study
por: Bringas, Mauro, et al.
Publicado: (2022)

Tocilizumab, Remdesivir, Favipiravir, and Dexamethasone Repurposed for COVID-19: a Comprehensive Clinical and Pharmacovigilant Reassessment
por: Kelleni, Mina T.
Publicado: (2021)

Insights on the Quantitative Concurrent Fluorescence-Based Analysis of Anti-COVID-19 Drugs Remdesivir and Favipiravir
por: El-Awady, Mohamed, et al.
Publicado: (2022)

Equal Ratio Ventilation Reduces Blood Loss During Posterior Lumbar Interbody Fusion Surgery
por: Kim, Hye Bin, et al.
Publicado: (2021)

In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase
por: Celik, Ismail, et al.
Publicado: (2021)

Evaluation of the Safety and Efficacy of Favipiravir in Adult Indian Patients with Mild-to-Moderate COVID-19 in a Real-World Setting
por: Reddy, Pavan Kumar, et al.
Publicado: (2022)

Eco-friendly spectrophotometric methods for determination of remdesivir and favipiravir; the recently approved antivirals for COVID-19 treatment
por: Elama, Heba Samir, et al.
Publicado: (2023)

Comparative assessment of favipiravir and remdesivir against human coronavirus NL63 in molecular docking and cell culture models
por: Wang, Yining, et al.
Publicado: (2021)

Remdesivir Is Associated With Reduced Mortality in COVID-19 Patients Requiring Supplemental Oxygen Including Invasive Mechanical Ventilation Across SARS-CoV-2 Variants
por: Mozaffari, Essy, et al.
Publicado: (2023)

Favipiravir and the Need for Early Ambulatory Treatment of COVID-19
por: Korman, Tony M.
Publicado: (2021)

Rapid and ecofriendly UPLC quantification of Remdesivir, Favipiravir and Dexamethasone for accurate therapeutic drug monitoring in Covid-19 Patient’s plasma
por: Emam, Aml A., et al.
Publicado: (2022)

Remdesivir in Severe COVID-19 and Non-Invasive Ventilation: A Real-Life Experience
por: Simioli, Francesca, et al.
Publicado: (2021)

Baricitinib + remdesivir cost saving vs remdesivir for hospitalised COVID-19 patients in the USA
Publicado: (2021)

Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19)
por: McCullough, Peter A.
Publicado: (2020)

Non-invasive ventilation with intelligent volume-assured pressure support versus pressure-controlled ventilation: effects on the respiratory event rate and sleep quality in COPD with chronic hypercapnia
por: Nilius, Georg, et al.
Publicado: (2017)

Spectrophotometric determination of favipiravir in presence of its acid hydrolysis product
por: Sharaf, Yasmine Ahmed, et al.
Publicado: (2023)

Diagnostic accuracy, clinical utility and influence on decision‐making of a methylation urine biomarker test in the surveillance of non‐muscle‐invasive bladder cancer
por: D'Andrea, David, et al.
Publicado: (2019)

CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer
por: Mostafid, A. Hugh, et al.
Publicado: (2020)

New fecal test for non-invasive Helicobacter pylori detection: A diagnostic accuracy study
por: Iannone, Andrea, et al.
Publicado: (2018)

The Recovery Physical Therapy Effects upon the Ventilation Dysfunction in Patients with Ankylosing Spondylitis
por: ROGOVEANU, O., et al.
Publicado: (2015)

Quantitative analysis of two COVID-19 antiviral agents, favipiravir and remdesivir, in spiked human plasma using spectrophotometric methods; greenness evaluation
por: Batubara, Afnan S., et al.
Publicado: (2023)

Development and validation of method for analysis of favipiravir and remdesivir in volumetric absorptive microsampling with ultra high-performance liquid chromatography–tandem mass spectrophotometry
por: Harahap, Yahdiana, et al.
Publicado: (2023)

Adjusted green spectrophotometric determination of favipiravir and remdesivir in pharmaceutical form and spiked human plasma sample using different chemometric supported models
por: Imam, Mohamed S., et al.
Publicado: (2023)

Canakinumab to reduce deterioration of cardiac and respiratory function in SARS‐CoV‐2 associated myocardial injury with heightened inflammation (canakinumab in Covid‐19 cardiac injury: The three C study)
por: Sheng, Calvin C, et al.
Publicado: (2020)

Favipiravir use for SARS CoV-2 infection
por: Boretti, Alberto
Publicado: (2020)

Benefit-risk assessment for remdesivir in COVID-19
Publicado: (2020)

Low-dose intralesional injection of 5-fluorouracil and triamcinolone reduces tissue resident memory T cells in chronic eczema
por: Wu, Yun, et al.
Publicado: (2022)

Clinical efficacy of electromagnetic field therapy combined with traditional Chinese pain-reducing paste in myofascial pain syndrome
por: Xiao, Jing, et al.
Publicado: (2022)

Nutritional supplement drink reduces inflammation and postoperative depression in patients after off-pump coronary artery bypass surgery
por: Matsushita, Satoshi, et al.
Publicado: (2021)

Remdesivir cost effective for severe COVID-19 in China
Publicado: (2021)

ICU admission and favipiravir
por: Mungmunpuntipantip, Rujittika, et al.
Publicado: (2021)

Novel environment friendly TLC-densitometric method for the determination of anti-coronavirus drugs “Remdesivir and Favipiravir”: Green assessment with application to pharmaceutical formulations and human plasma
por: Noureldeen, Deena A.M., et al.
Publicado: (2022)

Remdesivir Use in Patients Requiring Mechanical Ventilation due to COVID-19
por: Lapadula, Giuseppe, et al.
Publicado: (2020)

Reduced prevalence of SARS-CoV-2 infection in ABO blood group O
por: Barnkob, Mike Bogetofte, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_g4rnp8bgi9b0v35jsckc94lkit